"This is a new chapter… certainly a monumental decision, a monumental day that could lead to more significant changes," former Senator Cory Gardner (R-CO), NCR Advisory Member said in an exclusive interview with Benzinga discussing the Health and Human Services (HHS) groundbreaking recommendation to the DEA about reclassifying cannabis.
The transition from cannabis being a Schedule I drug, which considers it as having no medical value and places it alongside substances like heroin, to potentially becoming a Schedule III drug is indeed noteworthy. This move would acknowledge its medical value, which has been a long-standing debate in the federal sphere.
Gardner, former Rep. Ed Perlmutter (D-CO) and senior counsel at Akin Gump Strauss, Hauer & Feld LLP, Reggie Babin will sit down together at the upcoming Benzinga Cannabis Capital Conference in Chicago. Mark your calendar for September 27 and 28.
Cannabis & Politics: Is Schedule III The Future?
Speaking with Aaron Bry, content producer at Benzinga, Gardner provided an insightful perspective on the matter.
“I think in the characterizations of the steps today that I've heard, I've seen it described as monumental. I've seen it described as a very, very big event for the industry. And what it means… …